clinical trial · NCT00649662
Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg
HealthyCiprofloxacin Extended-Release Tablets 1000 mgCipro® XR Tablets 1000 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's ciprofloxacin extended-release 1000 mg tablets to Bayer's Cipro® XR 1000 mg tablets following a single, oral 1000 mg (1 x 1000 mg) dose administered under fasting conditions.
started
Oct 1, 2005
primary completion
Oct 1, 2005
completion
Oct 1, 2005
last updated
Apr 24, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Ciprofloxacin Extended-Release Tablets (1000 mg; Mylan) and Cipro® XR Tablets (1000 mg; Bayer) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol